Low molecular weight heparin: a promising anticoagulant in pregnancy

Bangal, Vidyadhar B; Giri, Purushottam A.; Chalasani, Shravani; Denita, Fernandes

doi:10.5455/2394-6040.ijcmph20141102

Cited by 1 publication

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many epidemiological studies have demonstrated that anticoagulant therapy not only prevents the occurrence of VTE in cancer patients but also may have a direct antitumor effect, thereby inhibiting tumor metastasis and prolonging patient survival [18]. LWMH is currently a commonly used anticoagulant drug with strong antithrombotic effect, long half-life, less bleeding side effects, and high safety [19]. In the present study, in the course of treatment for remission of VTE, we found that the total effective rate was 83.33% in CCRT with LWMH treatment, but the total effective rate was only 60% in CCRT without LWMH treatment.…”

Section: Discussionmentioning

confidence: 99%

The Abnormal Expression of miR-205-5p, miR-195-5p, and VEGF-A in Human Cervical Cancer Is Related to the Treatment of Venous Thromboembolism

Wang

Zhang

Tao

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

Background. Low molecular heparin (LWMH) therapy can prevent the occurrence of VTE in tumor patients and may have a direct antitumor effect. However, the expression pattern of VEGF-A and microRNAs was less reported in cervical cancer subjects who received concurrent chemoradiotherapy (CCRT) or received anticoagulant treatment with low molecular weight heparin (LWMH) after CCRT (CCRT+LWMH). Methods. In this study, 30 cervical cancer subjects treated with CCRT and 30 cervical cancer patients treated with CCRT+LWMH were enrolled. We screened five miRNAs (miR-15a-5p, miR-16-5p, miR-29a-3p, miR-195-5p, and miR-205-5p), which have multiple binding sites with VEGF-A and are highly expressed in serum of patients with cervical cancer, by RT-qPCR. The expression level of VEGF-A was also detected by RT-qPCR and ELISA. Statistical methods were used for difference and correlation analyses. Results. We observed the curative effect in the two treatment methods. In the CCRT group, the total effective rate was 60.00%, and in the CCRT+LWMT group, the total effective rate was 83.33% (P=0.013, χ2=6.129). Additionally, the serum levels of VEGF-A in the CCRT+LWMH group were downregulated, relative to the CCRT group (P<0.05), and VEGF-A in serum was significantly positively correlated with venous thromboembolism (VTE) (r=2.134, P=0.035). Only miR-205-5p and miR-195-5p were upregulated in CCRT+LWMH, relative to CCRT (P<0.05). In serum of patients with cervical cancer after CCRT+LWMH treatment, there was no significant correlation between VEGF-A and miR-15a-5p (r=−0.132, P=0.209), miR-16-5p (r=−0.205, P=0.311), or miR-29a-3p (r=−0.029, P=0.662), but VEGF-A was significantly negatively correlated with miR-195-5p (r=−0.396, P=0.040) and miR-205-5p (r=−0.315, P=0.032). Furthermore, VTE was also significantly negatively correlated with miR-195-5p (r=−0.412, P=0.031) and miR-205-5p (r=−0.123, P=0.044). Conclusion. These data revealed roles for VEGF-A and these miRNAs as potential biomarkers in cervical cancer patients with VTE, which exhibited usage potential in the treatment of venous thromboembolism.

show abstract

Section: Discussionmentioning

confidence: 99%